Top Markets
#1 Everything Everything +22.22%
#2 MarsCoin MarsCoin +10.14%
#3 Akedo Akedo +9.38%
#4 EXOD EXOD +9.04%
#5 peaq peaq +8.07%
#6 Solstice Solstice +7.47%
#7 The Black Bull The Black Bull +7.04%
#8 ETHGas ETHGas +6.30%
#9 Pons Pons +6.23%
#10 Peapods Finance Peapods Finance +6.22%
Coin of the day
Everything Everything
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Ambrx Biopharma Inc. Ambrx Biopharma Inc.

Ambrx Biopharma Inc.

AMAM
Classement en actions #6975
Ambrx Biopharma Inc. operates as a clinical-stage biotechnology company focused... Ambrx Biopharma Inc. operates as a clinical-stage biotechnology company focused on the discovery and development of precisely engineered biologic medicines. The firm utilizes its unique expanded genetic code technology platform to create these advanced therapies. Leading its pipeline is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is currently undergoing evaluation in several clinical investigations. These include pivotal Phase 2/3 trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer, alongside studies for other solid tumors. Additionally, Ambrx is progressing two earlier-stage drug candidates: ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for prostate cancer and other solid tumor indications; and ARX305, an anti-CD70 ADC, currently in investigational new drug (IND)-enabling studies for potential applications in renal cell carcinoma and other cancers. The company's portfolio also encompasses multiple immuno-oncology programs. Among these are ARX822, a fab-small molecule bispecific therapeutic in preclinical development for various cancers, and ARX102, an immuno-oncology IL-2 pathway agonist intended to stimulate the patient's immune system by targeting beta and gamma receptors on cytotoxic T cells. Founded in 2003 and headquartered in La Jolla, California, Ambrx Biopharma Inc. has established significant collaborations with various pharmaceutical partners, including Bristol Myers Squibb Company, AbbVie Inc., BeiGene, Sino Biopharmaceutical Co., Ltd., NovoCodex, and Elanco Animal Health.
Prix de l'action
$28.00
Dernière synchronisation: 2024-03-06
Capitalisation boursière
$1.77B
Changement (1 jour)
0.07%
Changement (1 an)
0.00%
Pays
US
Échange Ambrx Biopharma Inc. (AMAM)

Catégorie

Healthcare
Revenus pour Ambrx Biopharma Inc. (AMAM)
Revenus en Aug 2026 TTM : 0
Selon les derniers rapports financiers de Ambrx Biopharma Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Ambrx Biopharma Inc. de 2026 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
Pas assez de données pour les dates fournies.
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH